2024
Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET
Young J, O'Dell R, Naganawa M, Toyonaga T, Chen M, Nabulsi N, Huang Y, Cooper E, Miller A, Lam J, Bates K, Ruan A, Nelsen K, Salardini E, Carson R, van Dyck C, Mecca A. Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET. Journal Of Nuclear Medicine 2024, 65: jnumed.124.267419. PMID: 39299782, PMCID: PMC11533916, DOI: 10.2967/jnumed.124.267419.Peer-Reviewed Original ResearchDistribution volume ratioSUV ratioSynaptic densityEffect sizeAlzheimer's diseaseLongitudinal study of Alzheimer's diseaseMethods:</b> ParticipantsLongitudinal studyMeasure synaptic densityAD participantsStudy of Alzheimer's diseaseNormal cognitionReference regionOlder adultsMulticenterDensity alterationsIL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination
Park H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, Jeon S, You S, Racke M, Bucala R, Kang I. IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination. EBioMedicine 2024, 103: 105114. PMID: 38640835, PMCID: PMC11041015, DOI: 10.1016/j.ebiom.2024.105114.Peer-Reviewed Original ResearchConceptsCD4<sup>+</sup> T cellsCOVID-19 mRNA vaccinesAntigen-specific CD4<sup>+</sup> T cell responsesT cell responsesPrimary antibody deficiencyCD4<sup>+</sup> T cell responsesT cellsIL-1R1MRNA vaccinesIL-1IgG antibodiesAntigen-specific CD4<sup>+</sup> T cellsCD4+ T cell responsesLevels of IL-1R1Human CD4<sup>+</sup> T cellsIL-1 receptor 1Healthy individualsDose of COVID-19 mRNA vaccineAntigen-specific CD4IL-1R1 expressionT cell immunityRepetitive antigenic stimulationCytokines interleukin (IL)-1Immune response to virusesExpression of IL-1R1
2023
Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease
Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.Peer-Reviewed Original ResearchPeripheral bloodT cellsAlzheimer's diseaseEM CD8Memory CD8Gene signatureAge-related immune changesIL-7 receptor alphaEffector memory CD8Strong risk factorT cell expansionAD genesAge-associated expansionImmune changesRisk factorsCD8Dementia patientsIL-7RNeuropsychological testingReceptor alphaNeurocognitive functionRT-qPCR resultsDisease severityPatientsNormal personsModulating IL-1β and its receptors shapes spike-specific CD4 +T cell responses to mRNA vaccination
Park H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, You S, Racke M, Bucala R, Kang I. Modulating IL-1β and its receptors shapes spike-specific CD4 +T cell responses to mRNA vaccination. The Journal Of Immunology 2023, 210: 159.20-159.20. DOI: 10.4049/jimmunol.210.supp.159.20.Peer-Reviewed Original ResearchCOVID-19 mRNA vaccinesT cellsIL-1βIL-1R2MRNA vaccinesIL-1 receptor 1IL-1R1 expressionIL-1R2 expressionSpike-specific CD4Vaccine-induced CD4T cell immunityT cell responsesSpecific antibody productionMRNA vaccinationCell immunityDurable immunityIL-1R1IL-1BCD4Healthy individualsQuest DiagnosticsAntibody productionCell responsesReceptor 1Receptor system
2022
Implication of IL-7 receptor alpha chain expression by CD8+ T cells and its signature in defining biomarkers in aging
Shin M, Park H, Young J, Kang I. Implication of IL-7 receptor alpha chain expression by CD8+ T cells and its signature in defining biomarkers in aging. Immunity & Ageing 2022, 19: 66. PMID: 36544153, PMCID: PMC9768896, DOI: 10.1186/s12979-022-00324-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsT cellsImmune agingHost defenseIL-7 receptor alpha chainFrequencies of naïveT cell subsetsAlpha chain expressionAssociation of CD8Age-associated conditionsReceptor alpha chainMemory CD8Treatment of illnessCell subsetsInflammatory disordersIL-7RαCD8High riskImmune functionTherapeutic interventionsImmune systemPotential biomarkersGene signatureChain expressionOlder adultsBiomarkers
2019
Evidence-Based Pharmacological Management and Treatment of Behavioral and Psychological Symptoms of Dementia
Young J. Evidence-Based Pharmacological Management and Treatment of Behavioral and Psychological Symptoms of Dementia. American Journal Of Psychiatry Residents Journal 2019, 14: 3-5. DOI: 10.1176/appi.ajp-rj.2019.140602.Peer-Reviewed Original ResearchPersonality and the risk factors for developing behavioral and psychological symptoms of dementia: a narrative review
Young JJ, Balachandran S, Garg G, Balasubramaniam M, Gupta A, Tampi DJ, Tampi RR. Personality and the risk factors for developing behavioral and psychological symptoms of dementia: a narrative review. Neurodegenerative Disease Management 2019, 9: 107-118. PMID: 30998118, DOI: 10.2217/nmt-2018-0044.Peer-Reviewed Original ResearchAlcohol use disorder: How best to screen and intervene.
Dasarathy J, Young J, Chhatlani A, Raddock M, Tampi R. Alcohol use disorder: How best to screen and intervene. The Journal Of Family Practice 2019, 68: 35-39. PMID: 30724900.Peer-Reviewed Original ResearchConceptsAlcohol intakePsychotic disorders in late life: a narrative review
Tampi R, Young J, Hoq R, Resnick K, Tampi D. Psychotic disorders in late life: a narrative review. Therapeutic Advances In Psychopharmacology 2019, 9: 2045125319882798. PMID: 31662846, PMCID: PMC6796200, DOI: 10.1177/2045125319882798.Peer-Reviewed Original ResearchPsychotic disordersSignificant morbidityLater lifeNonpharmacological management strategiesDifferent clinical presentationsOlder adult populationClinical presentationAntipsychotic medicationPsychotropic medicationsVaried etiologyPotential etiologiesOptimizing outcomesTreatment approachesAdult populationNarrative reviewAdverse effectsDisordersJudicious useMorbidityMedicationsEtiologyMortalityRegular monitoringOutcomesLife
2018
Cannabinoids for the treatment of behavioral and psychological symptoms of dementia
Tampi R, Young J, Tampi D. Cannabinoids for the treatment of behavioral and psychological symptoms of dementia. Neurodegenerative Disease Management 2018, 8: 211-213. PMID: 30040030, DOI: 10.2217/nmt-2018-0019.Peer-Reviewed Original ResearchBenzodiazepine use and the risk for dementia
Tampi R, Tampi D, Young J, Banerjee A. Benzodiazepine use and the risk for dementia. Future Neurology 2018, 13: 209-217. DOI: 10.2217/fnl-2017-0040.Peer-Reviewed Original Research
2017
Frontotemporal dementia: latest evidence and clinical implications
Young J, Lavakumar M, Tampi D, Balachandran S, Tampi R. Frontotemporal dementia: latest evidence and clinical implications. Therapeutic Advances In Psychopharmacology 2017, 8: 33-48. PMID: 29344342, PMCID: PMC5761910, DOI: 10.1177/2045125317739818.Peer-Reviewed Original ResearchFTD syndromesFrontotemporal dementiaPharmacological interventionsSelective serotonin reuptake inhibitor (SSRI) treatmentSerotonin reuptake inhibitor treatmentPotential novel therapeutic targetDistinct neurobiological profilesReuptake inhibitor treatmentSide effect profileCurrent therapeutic modalitiesNovel therapeutic targetEffect profileClinical correlatesHistopathologic markersNonpharmacological interventionsNeurological syndromeClinical trialsTherapeutic modalitiesTherapeutic targetBehavioral symptomsUS FoodDrug AdministrationInhibitor treatmentCholinesterase inhibitorsLatest evidence
2016
Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder
Young J, Silber T, Bruno D, Galatzer-Levy I, Pomara N, Marmar C. Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder. Frontiers In Psychiatry 2016, 7: 72. PMID: 27199779, PMCID: PMC4843170, DOI: 10.3389/fpsyt.2016.00072.Peer-Reviewed Original Research
2014
A review of the relationship between proinflammatory cytokines and major depressive disorder
Young J, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. Journal Of Affective Disorders 2014, 169: 15-20. PMID: 25128861, DOI: 10.1016/j.jad.2014.07.032.Peer-Reviewed Original ResearchConceptsMajor depressive disorderProinflammatory cytokinesDepressive disorderCytokine profileSerum levelsIL-6IL-8 serum levelsHeterogeneity of MDDAnti-inflammatory treatmentPathogenesis of depressionAnti-inflammatory therapyElevated proinflammatory cytokinesElevated serum levelsProgression of MDDDevelopment of biomarkersInflammatory hypothesisMDD treatmentCSF levelsDepression medicationsMCP-1Inflammatory processMDD pathogenesisDepressed patientsPossible diagnostic toolAdjuvant properties